SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...

Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the ...

Medically reviewed by Nicholas R. Metrus, MD Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) are both diseases that affect your central nervous system ...

Increased consumer and medical professional knowledge regarding novel treatments is predicted to drive growth in the global amyotrophic lateral sclerosis (ALS) treatment market. The introduction ...

Amyotrophic lateral sclerosis (ALS) is a widespread neurodegenerative disease caused by the loss of neurons that control movement. Although abnormal accumulation of proteins called TDP-43 ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

The Food and Drug Administration (FDA) has granted accelerated approval to Qalsody ™ (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) who have a mutation in the ...

July 7, 2022 Degradation of motor neurons, conceptual computer illustration. Amyotrophic lateral sclerosis, also referred to as Lou Gehrig's disease is the most common of the motor neuron diseases.